These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 36190614)

  • 21. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
    Zhang C; Hu Y; Xiao W; Tian Z
    Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in CAR-T cells therapy for colorectal cancer.
    Qin X; Wu F; Chen C; Li Q
    Front Immunol; 2022; 13():904137. PubMed ID: 36238297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.
    Li H; Song W; Li Z; Zhang M
    Front Immunol; 2022; 13():992232. PubMed ID: 36353643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
    Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
    Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
    Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.
    Aparicio C; Belver M; Enríquez L; Espeso F; Núñez L; Sánchez A; de la Fuente MÁ; González-Vallinas M
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts.
    Van den Eynde A; Gehrcken L; Verhezen T; Lau HW; Hermans C; Lambrechts H; Flieswasser T; Quatannens D; Roex G; Zwaenepoel K; Marcq E; Joye P; Cardenas De La Hoz E; Deben C; Gasparini A; Montay-Gruel P; Le Compte M; Lion E; Lardon F; Van Laere S; Siozopoulou V; Campillo-Davo D; De Waele J; Pauwels P; Jacobs J; Smits E; Van Audenaerde JRM
    J Hematol Oncol; 2024 Feb; 17(1):8. PubMed ID: 38331849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
    Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
    Front Immunol; 2022; 13():871661. PubMed ID: 35911706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
    Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
    Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
    Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
    Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Forks in the road for CAR T and CAR NK cell cancer therapies.
    Dagher OK; Posey AD
    Nat Immunol; 2023 Dec; 24(12):1994-2007. PubMed ID: 38012406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural killer cells: a promising immunotherapy for cancer.
    Chu J; Gao F; Yan M; Zhao S; Yan Z; Shi B; Liu Y
    J Transl Med; 2022 May; 20(1):240. PubMed ID: 35606854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
    Li Y; Rezvani K; Rafei H
    Immunol Rev; 2023 Nov; 320(1):217-235. PubMed ID: 37548050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.
    Marofi F; Saleh MM; Rahman HS; Suksatan W; Al-Gazally ME; Abdelbasset WK; Thangavelu L; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Pathak Y; Naimi A; Baradaran B; Nikoo M; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):374. PubMed ID: 34215336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments.
    Li X; Li W; Xu L; Song Y
    Chin Med J (Engl); 2024 Jun; 137(11):1285-1302. PubMed ID: 37640679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
    Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
    Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineering Natural Killer Cells for Cancer Immunotherapy.
    Rezvani K; Rouce R; Liu E; Shpall E
    Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.